Study of SYHA1813 for recurrent or progressive high-grade meningioma
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new drug, SYHA1813, for people with a type of brain tumor called high-grade meningioma that has come back or gotten worse. The goal is to see if the drug can help control the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with a WHO grade II or III meningioma (a type of brain tumor).
- You have at least one tumor that can be measured on an MRI scan.
- You are able to take care of yourself (KPS score of 60 or higher).
- Your doctor expects you to live at least 3 more months.
- You have not had certain other cancers in the last 3 years, except for some skin cancers or early-stage cancers that are cured.
- You are not taking more than 5 mg of dexamethasone (a steroid) daily within 7 days before starting the trial.
- You are not currently taking certain medications that could interact with the study drug (like strong CYP3A4 inhibitors or anticoagulants).
- You are able to have MRI scans with contrast dye.
- You do not have severe bleeding problems, uncontrolled infections, or major heart or blood vessel disease.
- You have not had major surgery within the last 28 days.
- You have not had chemotherapy, targeted therapy, immunotherapy, or other anti-cancer treatments within the last 28 days.
- You are not pregnant or breastfeeding, and you agree to use effective birth control if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, SYHA1813, for people whose high-grade meningioma has come back or gotten worse after standard treatments like surgery and radiation. The goal is to see if this drug can help control the tumor and improve outcomes.
This trial tests an experimental cell therapy (MT027) for people with high-grade brain tumors that have come back or stopped responding to treatment. It targets a protein called B7-H3 found on tumor cells, aiming to attack the cancer.
This study tests a new drug called JZP3507 for people with meningioma (a type of brain tumor, grades 2 or 3) that has come back or grown despite previous treatment. The goal is to see if this medication can slow or shrink the tumor.
This trial tests an experimental drug called HX301 for people with high-grade gliomas (fast-growing brain tumors). It is for patients whose tumor has come back after temozolomide chemo, or for those with newly diagnosed glioblastoma that has been surgically removed. The study aims to see if HX301 can help control the tumor.
This trial studies NEO100, a treatment for adults and children (age 12+) with Grade II or III meningioma that has come back or kept growing after surgery and radiation. It may help shrink tumors or slow growth when standard options have not worked well enough.
This early-stage trial tests a new drug called YSCH-01, alone or combined with an immunotherapy drug (atezolizumab), for glioblastoma that has come back after previous treatment. The study places a small tube in the brain to deliver the drug directly and monitors safety and how well it works.
Hear when a new Recurrent or Progressive High Grade Meningioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.